Fig. 7
Light-responsive chemotherapeutic drug delivery and imaging systems for bone tumors. A Schematic diagram of the therapeutic mechanisms of BTZ@ZnPc-ALN for chemo-photodynamic therapy for bone metastatic breast cancer. B Cytosolic Ca2+ levels detection of MDA-MB-231 cells by confocal laser scanning microscopy using Fluo-3-AM as probe after different treatments. Scale bar: 50 μm. C Intracellular ROS production and cytosolic Ca2+ levels detection of MDA-MB-231 cells by flow cytometry. D Western blot analysis of ERS-related protein GRP78 and apoptosis-related protein BCL-2 after different treatments. Reproduced with permission [99]. Copyright 2020, Elsevier. E Schematic illustration of the synthetic and therapeutic mechanisms of UCNP/Ce6@mMnO2/DSP-TFA (U6MDT) for image-guided PDT-chemotherapy combination for the treatment of NSCLC-SM. F NIR fluorescence images and H signal intensity analysis of the NSCLC-SM mouse model at different times after intravenous injection of U6MDT. G Images of spinal vertebral tumors of each group in panel I after 4 weeks of treatment. I Body weight, J survival curve, K tumor weight and L tumor volume of NSCLC-SM model in different treatment groups (*p < 0.05, **p < 0.01 and ***p < 0.001). Reproduced with permission [94]. Copyright 2022, American Chemical Society